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The liver plays important roles in multiple processes including metabolism, the immune
system, and detoxification and also has a unique capacity for regeneration. FGFs are
growth factors that have diverse functions in development, health, and disease. The
FGF family now comprises 22 members. Several FGFs have been shown to play roles
as paracrine signals in liver development, health, and disease. FGF8 and FGF10 are
involved in embryonic liver development, FGF7 and FGF9 in repair in response to liver
injury, and FGF5, FGF8, FGF9, FGF17, and FGF18 in the development and progression
of hepatocellular carcinoma. In contrast, FGF15/19 and FGF21 are endocrine signals.
FGF15/19, which is produced in the ileum, is a negative regulator of bile acid metabolism
and a stimulator of gallbladder filling. FGF15/19 is a postprandial, insulin-independent
activator of hepatic protein and glycogen synthesis. It is also required for hepatocellular
carcinoma and liver regeneration. FGF21 is a hepatokine produced in the liver. FGF21
regulates glucose and lipid metabolism in white adipose tissue. Serum FGF21 levels
are elevated in non-alcoholic fatty liver. FGF21 also protects against non-alcoholic fatty
liver. These findings provide new insights into the roles of FGFs in the liver and potential
therapeutic strategies for hepatic disorders.
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INTRODUCTION
The prototypic fibroblast growth factors (FGFs), FGF1 and FGF2, which were originally isolated
from the brain as growth factors for fibroblasts, are multi-functional signaling proteins of ∼150
amino acids that exert diverse activities in cell proliferation, angiogenesis, neuronal cell growth
and survival, and wound healing with widespread expression profiles in embryos and adults
(Burgess and Maciag, 1989; Baird and Klagsbrun, 1991). The FGF family now comprises 22
members including FGF1–FGF23 in humans and mice. These FGFs also have diverse functions
in development, health, and disease. The human and mouse FGF families do not include FGF15 or
FGF19, respectively, because they are orthologs. Although these orthologs have been named FGF15
in rodents and FGF19 in other vertebrates, they are typically referred to as FGF15/19 (Goetz and
Mohammadi, 2013; Ornitz and Itoh, 2015).
The liver, which is the largest organ in the body, plays important roles in multiple processes
including catabolism and anabolism, the immune system, and detoxification. The liver also has a
unique capacity for regeneration with the potential for the full restoration of livermass and function
even following massive damage (Taub, 2004; Bhatia et al., 2014). Several FGFs function as paracrine
or endocrine signals in liver development, health, and disease. These findings provide new insights
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into the roles of FGFs in the liver and potential therapeutic
strategies for hepatic disorders. A succinct review of the roles of
FGFs in the liver is provided herein.
THE FGF FAMILY
The FGF family includes 22 FGF proteins of ∼150–300
amino acids with a conserved core (∼30–60% amino acid
identity) of ∼120 amino acids. Phylogenetic analyses of the
FGF family have revealed potential evolutionary relationships
with seven subfamilies in this family. FGFs have been classified
into paracrine, endocrine, and intracrine FGFs based on
their mechanisms of action (Figure 1). Mice lacking these
FGFs indicate their crucial roles in development and health.
Paracrine FGFs, which comprise 15 members, are locally secreted
signals that mainly function in multiple developmental and
physiological processes. Endocrine FGFs, which comprise three
members, are secreted endocrine signals that mainly function in
multiple metabolic processes. FGF gene variations in humans
also result in various diseases. These findings indicate that
paracrine and endocrine FGFs are crucial for ensuring proper
development and health in mice and humans. In contrast,
intracrine FGFs, which comprise four members, are not secreted
signals that play roles in the regulation of electrical excitability in
neurons in an intracrine manner (Goetz and Mohammadi, 2013;
Ornitz and Itoh, 2015). Several paracrine and endocrine FGFs,
but not intracrine FGFs are involved in liver development, health,
and disease as described below.
FIGURE 1 | Evolutionary relationships within the human FGF family.
Phylogenetic analyses suggest that 22 members of the FGF family are
classified into seven subfamilies including the FGF1/2, FGF3/7/10/22,
FGF4/5/6, FGF8/17/18, FGF9/16/20, FGF11/12/13/14, and FGF15/19/21/23
subfamilies. Branch lengths are proportional to the evolutionary distance
between each FGF. FGFs are also classified into paracrine, endocrine, and
intracrine FGFs based on their mechanisms of action. Of these, FGF5, FGF7,
FGF8, FGF9, FGF10, FGF17, FGF18, FGF15/19, and FGF21 play roles in liver
development, health, and disease.
ROLES OF PARACRINE FGFs IN THE LIVER
Paracrine FGFs, which comprise 15 members including FGF1-
FGF6, FGF7-FGF10, FGF16-FGF18, FGF20, and FGF22, have
a secreted signal sequence and heparan sulfate-binding site at
their amino and carboxyl termini, respectively (Figures 1, 2A).
Paracrine FGFs act on nearby target cells as locally secreted
signals via diffusion. Heparan sulfate chains, which are long
linear carbohydrate chains of repeating sulfated glucuronic
acid linked to N-acetylglucosamine disaccharides, are covalently
linked to specific cell surface transmembrane-type proteins.
Heparan sulfate functions to sequester FGFs and modulate their
diffusion. This modulation of diffusion directs paracrine FGFs as
local signals (Figures 2B, 3; Goetz andMohammadi, 2013; Ornitz
and Itoh, 2015).
Paracrine FGFs mediate biological responses by binding
to cell surface FGF receptors (FGFRs) with heparan sulfate
as a co-factor. Seven major FGFR proteins (FGFRs 1b,
1c, 2b, 2c, 3b, 3c, and 4) with differing ligand-binding
specificities are generated from the FGFR1, FGFR2, FGFR3,
and FGFR4 genes by alternative splicing. Heparan sulfate
is necessary for stable interactions with FGFRs, and also
independently interacts with FGFs and FGFRs. The FGF-
FGFR-heparan sulfate complex leads to FGFR dimerization,
which directs the activation of FGFR intracellular tyrosine
kinase domains, followed by that of key intracellular signaling
pathways including the RAS-mitogen-activated protein kinase
FIGURE 2 | (A) Schematic representations of paracrine and endocrine FGF
structures. SP, HB, and KLB indicate a secreted signal sequence, heparan
sulfate-binding site, and Klotho-binding site, respectively. (B) Mechanisms of
action of paracrine and endocrine FGFs. Paracrine FGFs are locally secreted
signals that act on nearby target cells by diffusion, with functions in multiple
developmental and physiological processes. Endocrine FGFs are secreted
endocrine signals that act on distant target cells through the bloodstream, with
functions in multiple metabolic processes. FGFR-HS and FGFR-Klotho indicate
the FGFR-heparan sulfate complex and FGFR-Klotho complex, respectively.
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FIGURE 3 | Mechanisms of action of paracrine and endocrine FGFs.
Paracrine FGFs specifically bind to the FGFR-heparan sulfate complex and
activate FGFR tyrosine kinase. This activation, in turn, induces the activation of
the RAS–MAPK, PI3K–AKT, PLCγ, and STAT pathways. Endocrine FGFs
specifically bind to the FGFR-Klotho complex and activate tyrosine kinase.
This activation, in turn, induces the activation of intracellular pathways.
(MAPK), phosphoinositide 3-kinase (PI3K)-AKT, phospholipase
Cγ (PLCγ), and signal transducer and activator of transcription
(STAT) pathways (Figure 3; Goetz and Mohammadi, 2013;
Ornitz and Itoh, 2015).
Development
The definitive endoderm, one of the embryonic germ layers,
produces the gut tube and associated organs including the liver,
lungs, and pancreas. Liver development, which is initiated by
liver budding, occurs through reciprocal inductive interactions
between the endoderm and underlying mesoderm. Secreted
signals from the mesoderm to the endoderm are essential
for liver budding. These secreted signals include FGFs, bone
morphogenetic proteins (BMPs), andWnts (Calmont et al., 2006;
Tremblay, 2010). FGF8 and FGF10 play roles as paracrine signals
in liver development (Table 1).
FGF8 as a Morphogen
FGF8 mainly activates FGFR1c with heparan sulfate as a co-
factor. FGF8 is expressed in the adjacent mesoderm in the
early embryonic stages, indicating its involvement in liver
development (Crossley and Martin, 1995; Calmont et al., 2006;
Wang et al., 2015). Since FGF8 knockout mice, which are lethal
at the gastrulation stage, lack all embryonic mesoderm and
endoderm-derived structures, the examination of its roles in liver
development has been precluded (Sun et al., 1999). However,
FGF8 is required for anterior heart field development; therefore,
FGF8 is also expected to be required for liver development
(Table 1; Ilagan et al., 2006).
TABLE 1 | Roles of paracrine/endocrine FGFs in the liver.
FGFs Roles Species
PARACRINE FGFs
FGF8 A morphogen in liver development Mice
FGF10 A morphogen in liver development Mice
FGF7 A repair factor for liver injury Mice/Humans
FGF9 A repair factor for liver injury Mice
FGF5 A protector for NASH induced by a high-fat diet Mice
FGF8 A progressor in HCC Humans
FGF17 A progressor in HCC Humans
FGF18 A progressor in HCC Humans
FGF5 A target of miRNA in HCC Humans
FGF9 A target of miRNA in HCC Humans
ENDOCRINE FGFs
FGF15/19 An ilium-derived regulator in hepatic bile acid,
protein, and, glycogen metabolism
Mice
FGF21 A liver-derived regulator in glucose and lipid
metabolism
Mice
FGF21 A liver-derived protector for NAFLD/NASH Mice/Humans
FGF15/19 An ilium-derived factor in liver regeneration Mice
FGF15/19 An ilium-derived progressor in HCC Mice/Humans
FGF10 as a Morphogen
FGF10 preferentially activates FGFR2b with heparan sulfate as
a co-factor. FGF10 is also expressed in the adjacent mesoderm
in the early embryonic stages, indicating its involvement in
liver development (Kelly et al., 2001). FGF10 knockout mice
are lethal shortly after birth due to the lack of multiple
organs including limbs and lungs (Sekine et al., 1999). In
addition, FGF10 knockout mice with smaller livers exhibit the
reduced proliferation and survival of hepatoblasts, indicating that
FGF10 is required for liver growth during embryogenesis and
hepatoblast growth (Table 1; Berg et al., 2007).
Repair
The liver mainly comprises two types of cells: parenchymal
(hepatocytes) and non-parenchymal cells. Hepatocytes, which
account for ∼80% of hepatic cells, perform most metabolic
functions in the liver. Hepatocytes also maintain the ability to
proliferate in response to toxic injury and infection (Taub, 2004).
FGF7 and FGF9 play roles as paracrine signals in liver repair
(Table 1).
FGF7 as a Repair Factor
FGF7 preferentially activates FGFR2b with heparan sulfate as
a co-factor. FGF7 is a paracrine FGF expressed in multiple
tissues including the cerebrum, lungs, vas deferens, tongue, and
skin in the postnatal stages (Fon Tacer et al., 2010). When
hepatocyte proliferation is impaired by severe liver damage,
facultative liver progenitor cells proliferate and contribute to
repair. The expansion of liver progenitor cells is also often
observed in patients with liver diseases. FGF7 knockout mice,
which are viable, have impaired hair, kidney, and neuronal
synapse development, but not impaired liver development (Guo
et al., 1996; Qiao et al., 1999; Terauchi et al., 2010). However,
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liver progenitor cell expansion and higher mortality upon
toxin-induced hepatic injury are markedly depressed in FGF7
knockout mice. In contrast, liver progenitor cells are induced
and hepatic dysfunction is ameliorated in FGF7 transgenic mice.
The expression of FGF7 is also induced concomitantly with liver
progenitor cell responses in the livers of mouse models as well as
in the serum of patients with acute liver failure. These findings
indicate that FGF7 is a critical regulator of liver progenitor cells
in liver injury (Table 1; Takase et al., 2013).
FGF9 as a Repair Factor
FGF9 mainly activates FGFR1c with heparan sulfate as a co-
factor. FGF9 is broadly expressed at high levels throughout the
brain and in the kidney in the postnatal stages (Fon Tacer et al.,
2010). FGF9 knockout mice are lethal at the neonatal stage due
to lung hypoplasia, but do not have impaired livers (Colvin
et al., 2001). Hepatic injury is associated with the activation of
hepatic stellate cells. The expression of FGF9 is increased in
hepatic stellate cells in liver slice cultures after exposure to carbon
tetrachloride as an acute liver injury model. FGF9 significantly
stimulates the incorporation of thymidine by hepatocytes. These
findings indicate that FGF9 provides a paracrine mitogenic signal
to hepatocytes during acute liver injury (Table 1; Antoine et al.,
2007).
Non-alcoholic Fatty Liver Disease (NAFLD)
NAFLD includes metabolic liver disorders ranging from simple
fatty liver (hepatic steatosis) to non-alcoholic steatohepatitis
(NASH) and liver cirrhosis. NAFLD, which has high morbidity
and mortality rates, is regarded as a serious public health issue.
The main risk factors for NAFLD are obesity, dyslipidemia, and
insulin resistance. A multi-hit process including lipotoxicity,
oxidative stress, endoplasmic reticulum stress, and an
inflammatory state has been implicated in the pathogenesis
of NAFLD (Takaki et al., 2013; Demir et al., 2015). FGF5
functions as a paracrine signal in NASH (Table 1).
FGF5 Knockout Mice Fed a High-Fat Diet
with the Characteristics of NASH
FGF5 is expressed throughout the central nervous system and is
also present in the skin in the postnatal stages (Fon Tacer et al.,
2010). FGF5 knockout mice with the long hair phenotype are
viable and appear to be healthy (Hébert et al., 1994). However,
FGF5 knockoutmice fed a high-fat diet gain little weight and have
higher serum alanine transaminase, aspartate amino transferase,
and non-high-density lipoprotein-cholesterol levels. Their liver
histology indicates marked inflammation, focal necrosis, fat
deposition, and fibrosis, which are similar to the characteristics
of NASH. However, the mechanisms underlying the associations
between FGF5, high-fat diet, andNASH currently remain unclear
(Table 1; Hanaka et al., 2014).
Hepatocellular Carcinoma (HCC)
HCC is the most common type of liver cancer and has a poor
prognosis. Most cases of HCC are secondary to a viral hepatitis
infection or cirrhosis. Hepatocarcinogenesis in cirrhosis involves
multiple processes, in which precancerous dysplastic nodules
transform into early HCC, progressed HCC, and advanced HCC
(Forner et al., 2012; Schulze et al., 2015). FGF signaling plays
crucial roles in HCC. FGFR3 and FGFR4, which are the main
FGFRs expressed in the liver, are involved in HCC (Qiu et al.,
2005; French et al., 2012). FGFR2 has also been shown to play a
role in HCC (Harimoto et al., 2010). In addition, FGF8, FGF17,
and FGF18 act as paracrine signals in HCC. FGF5 and FGF9 are
also targets of miRNAs in HCC (Table 1).
FGF8, FGF17, and FGF18 as Progressors
FGF8, FGF17, and FGF18 are members of the FGF8/7/18
subfamily (Figure 1). These FGFs mainly activate FGFR1c with
heparan sulfate as a co-factor. At least one member of the
FGF8/17/18 subfamily is up-regulated in 59% of 34 human
HCC cases. The expression of subfamily members is markedly
increased in culturedHCC cells subjected to serumwithdrawal or
a hypoxia-mimetic drug. The addition of FGF8, FGF17, or FGF18
impairs apoptosis, the incidence of which is elevated in serum-
starved cells. In contrast, the down-regulation of FGF18 by small
interfering RNA significantly reduces the viability of HCC cells.
FGF8, FGF17, and FGF18 are involved in autocrine/paracrine
signaling in HCC and enhance the survival of tumor cells.
These findings indicate that FGF8 subfamily members support
the development and progression of hepatocellular malignancy
(Table 1; Gauglhofer et al., 2011).
FGF5 and FGF9 as Targets of microRNA
(miRNAs)
miRNAs are highly conserved small non-coding regulatory RNAs
that negatively regulate gene expression by binding directly to
corresponding target mRNAs in a sequence-specific manner
(Giordano and Columbano, 2013). miR-188-5p is significantly
decreased in HCC cells and strongly correlates with multiple
nodules, microvascular invasion, and the overall and disease-
free survival of HCC. The ectopic expression of miR-188-5p
suppresses HCC cell proliferation and metastasis. The enforced
expression of miR-188-5p significantly inhibits the expression
of FGF5, while the restoration of FGF5 expression reverses
the inhibitory effects of miR-188-5p on HCC cell proliferation
and metastasis. These findings indicate a tumor suppressor
role for miR-188-5p via the targeting of FGF5, which mainly
activates FGFR1c with heparan sulfate as a co-factor in human
HCC (Table 1; Fang et al., 2015). Furthermore, miR-140-5p
suppresses tumor growth and metastasis by targeting FGF9,
which also mainly activates FGFR1c with heparan sulfate as a
co-factor, in human HCC (Table 1; Kuro-o, 2012; Yang et al.,
2013).
ROLES OF ENDOCRINE FGFs IN THE
LIVER
Endocrine FGFs, which comprise three members: FGF15/19,
FGF21, and FGF23, have a secreted signal sequence and Klotho-
binding site at their amino and carboxyl termini (Figure 2A). In
contrast to paracrine FGFs, endocrine FGFs do not function as
local signals due to their lower heparan sulfate-binding affinity.
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They require αKlotho or βKlotho as a co-factor for FGFR.
αKlotho and βKlotho are specifically expressed in the target
tissues of endocrine FGFs, which function in an endocrine
manner with target-tissue specificity through the bloodstream
(Figure 2B; Goetz and Mohammadi, 2013; Ornitz and Itoh,
2015).
αKlotho and βKlotho, which share structural similarities and
characteristics with each other, are single-pass transmembrane
proteins of∼1000 amino acids with a short cytoplasmic domain.
However, endocrine FGFs cannot efficiently bind to FGFR,
αKlotho, or βKlotho alone; they efficiently bind to the FGFR-
Klotho complex. FGF15/19 activates FGFR4 with βKlotho and
FGF21 activates FGFR1c with βKlotho, which, in turn, induces
the activation of intracellular signaling pathways (Figure 3;
Beenken and Mohammadi, 2012; Kuro-o, 2012). FGF15/19
exhibits metabolic and proliferative activities. However, FGF21 is
a unique FGF with metabolic, but no proliferative activity (Goetz
and Mohammadi, 2013; Ornitz and Itoh, 2015).
Metabolism
The liver plays important roles in multiple catabolic and anabolic
pathways including bile acids, lipids, and carbohydrates, in
addition to detoxification (Taub, 2004; Bhatia et al., 2014).
FGF15/19 acts as an endocrine signal in bile acid metabolism
in the liver. FGF21 also functions as an endocrine hepatokine in
glucose and lipid metabolism (Table 1).
FGF15/19 as a Regulator of Bile Acid
Metabolism
Most FGF15/19 knockout mice gradually die after embryonic day
(E) 10.5 due to defects in the cardiac outflow tract, indicating that
FGF15/19 plays a crucial role in embryonic heart development
(McWhirter et al., 1997; Vincentz et al., 2005). However, few
FGF15/19 knockout mice survive, even after the postnatal stages.
In the postnatal stages, FGF15/19 is preferentially expressed
in the ileum. Bile acids, which are synthesized in the liver,
promote the digestion and absorption of dietary fat by forming
micelles. The liver and intestines play crucial roles in maintaining
bile acid homeostasis. Cholesterol 7α-hydroxylase (CYP7A1)
catalyzes the first and rate-limiting step in the bile acid synthetic
pathway in the liver. The expression of FGF15/19 in the ileum
is induced by the nuclear bile acid receptor FXR. The induction
of FGF15/19 represses CYP7A1 expression in the liver in an
endocrine manner. Surviving FGF15/19 knockout mice have
higher CYP7A1 expression levels and enhanced fecal bile acid
excretion, indicating that FGF15/19 plays a crucial role in bile
acid synthesis as a gut-liver signal in an endocrine manner
(Table 1; Inagaki et al., 2005). The cycle of gallbladder filling and
emptying controls the flow of bile into the intestines for digestion.
Gallbladders in surviving FGF15/19 knockout mice are almost
devoid of bile. The gallbladder volume in surviving FGF15/19
knockout mice is significantly increased by an injection of the
FGF15/19 protein. These findings indicate that FGF15/19 also
plays crucial roles in gallbladder filling (Table 1; Choi et al., 2006).
FGF15/19 stimulates hepatic protein and glycogen synthesis,
but does not induce lipogenesis. Surviving FGF15/19 knockout
mice fail to properly maintain blood concentrations of glucose
and normal postprandial amounts of liver glycogen. FGF15/19
treatments restore the loss of glycogen in streptozotocin-treated
mice that are diabetic and have no detectable blood insulin levels.
These findings indicate that FGF15/19 is a postprandial, insulin-
independent activator that acts directly on the liver via hepatic
protein and glycogen synthesis (Table 1; Kir et al., 2011).
FGF21 as a Hepatokine in Glucose and
Lipid Metabolism
Liver-derived cytokines are known to function as hepatokines
and include angiopoietin-related protein 6, fetuin-A, insulin-
like growth factors, and selenoprotein P. Hepatokines directly
regulate glucose and lipid metabolism (Stefan and Häring,
2013). FGF21, which is abundantly expressed in the liver, also
plays roles as a hepatokine in glucose and lipid metabolism
in white adipose tissue (Itoh, 2014). Although hepatic FGF21
is generally expressed at low levels, its expression is strongly
induced during fasting through the activation of peroxisome
proliferator-activated receptor α (PPARα) by the non-esterified
fatty acids released from adipocytes and taken up by hepatocytes
(Murata et al., 2011). FGF21 knockout mice are viable, fertile,
and appear to be normal. Lipolysis in white adipose tissue is
enhanced in fasted Fgf21 knockout mice, indicating that FGF21
inhibits lipolysis during fasting (Hotta et al., 2009). Hepatic Fgf21
expression is also significantly induced by a low-carbohydrate,
high-fat ketogenic diet. Insulin sensitivity in white adipose
tissue is impaired by ketogenic diet feeding. This impaired
sensitivity is improved in FGF21 knockout mice, indicating that
FGF21 is a negative regulator of adipocyte insulin sensitivity in
adaptation to a low-carbohydrate malnutritional state (Murata
et al., 2013). Hepatic FGF21 induced by starvation also increases
systemic glucocorticoid levels and suppresses physical activity in
adaptation to starvation responses. These effects in mice were
not observed in perfused livers or cultured hepatocytes (Ogawa
et al., 2007; Potthoff et al., 2009). In addition, most of these effects
have not been observed in mice lacking β-Klotho in the brain or
those lacking FGFR1 in adipose tissue (Adams et al., 2010; Owen
et al., 2014). These findings indicate that hepatic FGF21 exerts
diverse actions through FGFR1c/β-Klotho in the brain or adipose
tissue, but not directly on the liver. Hepatic FGF21 expression
is also significantly induced by different kinds of stresses such
as hepatic injury, chemical insults, and diseases, indicating that
hepatic FGF21 is a stress-induced metabolic regulator (Table 1;
Cheng et al., 2014).
Adiponectin is a white adipocyte-derived hormone. Studies on
FGF21 knockout mice have also indicated that hepatic FGF21
is an upstream effector of adiponectin that mediates many of
the systemic effects of FGF21 on energy metabolism and insulin
sensitivity in the liver and skeletal muscle (Holland et al., 2013;
Lin et al., 2013). Glucagon regulates glucose and lipidmetabolism
and promotes weight loss. Glucagon receptor activation increases
hepatic FGF21 expression. Findings obtained from FGF21
knockout mice suggest that hepatic FGF21 contributes, at least
in part, to glucose, energy, and lipid metabolism controlled by
glucagon (Habegger et al., 2013). FGF21 knockout mice also
exhibit insulin resistance while being normoglycemic, and this
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is associated with increases in pancreatic beta-cell proliferation
and insulin synthesis, which act as compensatory responses. This
resistance results from enhanced growth hormone sensitivity
in FGF21 knockout pancreatic islets, indicating that hepatic
FGF21 is important for the regulation of pancreatic beta-cell
proliferation and insulin synthesis, possibly via the modulation
of growth hormone signaling (So et al., 2015). Endoplasmic
reticulum (ER) stress leads to the development and progression
of various diseases such as obesity and diabetes. ER stress
induces hepatic FGF21 expression. ER stress and the hepatic
accumulation of lipids are enhanced in FGF21 knockout mice,
indicating that FGF21 plays a role in adaptive responses to ER
stress (Table 1; Kim et al., 2015).
NAFLD
As described above, NAFLD includes metabolic liver disorders
ranging from hepatic steatosis to NASH and liver cirrhosis.
FGF21 plays roles in NAFLD (Table 1).
FGF21 as a Protective Factor for NAFLD
Serum FGF21 levels are significantly increased in patients with
hepatic steatosis and NASH in a manner that is dependent on
the degree of steatosis (Yilmaz and Eren, 2012; Shen et al., 2012,
2013; Li et al., 2013; Liu et al., 2015). Mice fed a high-fat diet
or methionine/choline-deficient diet are model mice for NASH.
Serum FGF21 levels and hepatic FGF21 expression levels are also
significantly higher in these mice (Xu et al., 2009; Tanaka et al.,
2015). As described above, FGF21 is an important metabolic
regulator of glucose and lipid metabolism. The administration
of a high dose of intravenous FGF21 reverses hepatic steatosis,
improves insulin sensitivity, and decreases serum glucose levels
in mice with NAFLD (Xu et al., 2009). These findings indicate
that elevated serum FGF21 levels may be a protective response
against glucose-lipid metabolism disorders in patients and mice
with NAFLD/NASH (Table 1).
Metformin decreases hepatic gluconeogenesis and increases
hepatic fatty acid β-oxidation by activating AMPK (Doycheva
and Loomba, 2014). In cultured hepatocytes, metformin
stimulates the expression of FGF21, which is inhibited by
an AMPK inhibitor, indicating that FGF21 may contribute
to the therapeutic effects of metformin on NAFLD (Nygaard
et al., 2012). However, metformin is not beneficial for patients
with NAFLD (Mazza et al., 2012). The nicotinamide adenine
dinucleotide-dependent deacetylase sirtuin 1 (SIRT1) tightly
regulates fatty acid metabolism in the liver. Prolonged fasting
induces lipid deposition in the livers of wild-type mice, but
severe hepatic steatosis in liver-specific SIRT1 knockout mice.
Fasting increases the expression of FGF21 in the livers of wild-
type mice, but not in those of liver-specific SIRT1 knockout mice.
Decreased hepatic FGF21 expression and serum FGF21 levels in
fasted liver-specific SIRT1 knockout mice have been correlated
with the decreased hepatic expression of genes involved in fatty
acid oxidation and ketogenesis, and increased expression of
genes that control lipogenesis. The SIRT1 activator, resveratrol,
increases FGF21 mRNA and FGF21 protein levels in human
liver carcinoma HepG2 cells. The hepatic overexpression of
FGF21 in liver-specific SIRT1 knockout mice increases the
expression of genes involved in fatty acid oxidation, thereby
decreasing fasting-induced steatosis, reducing obesity, increasing
energy expenditure, and promoting the browning of white
adipose tissue. These findings indicate that the SIRT1-mediated
activation of FGF21 prevents liver steatosis caused by fasting
(Table 1; Li et al., 2014).
Regeneration
Hepatocytes, which are long lived, normally do not undergo
cell division. After the surgical removal of two-thirds of the
liver in mice, the remaining liver enlarges until the original
liver is restored. The liver has a strong regenerative capacity
due to hyperplastic responses that involve the replication of
all mature functioning cells in the remnant liver without the
recruitment of liver stem cells or progenitor cells (Taub, 2004).
FGF15/19 functions as an endocrine signal in liver regeneration
(Table 1).
FGF15/19 as a Regenerative Factor
As described above, FGF15/19 is preferentially expressed in
the ileum. After 2/3 partial hepatectomy, FGF15/19 knockout
mice display more extensive liver necrosis and greater elevations
in serum bile acid and bilirubin levels than wild-type mice.
In addition, hepatocyte proliferation is reduced in FGF15/19
knockout mice because of impaired cell cycle progression,
indicating that FGF15/19 is required for liver regeneration.
The underlying mechanisms are likely the result of disrupted
bile acid homeostasis and the impaired priming of hepatocyte
proliferation (Table 1; Uriarte et al., 2013; Kong et al.,
2014).
HCC
As described above, HCC is the most common type of liver
cancer, in which FGF15/19 plays roles (Table 1).
FGF15/19 as a Progressor
Fewer and smaller tumors with smaller histological neoplastic
lesions are observed in FGF15/19 knockout mice subjected
to a clinically relevant model of liver inflammation and
fibrosis-associated carcinogenesis. Ileal FGF15/19 expression is
stimulated in mice undergoing carcinogenesis. Hepatocellular
proliferation and fibrogenesis are also reduced in FGF15/19
knockout mice. In vitro experiments indicate that liver
fibrogenic stellate cells are not direct targets for FGF15/FGF19.
FGF15/FGF19 as an endocrine factor induces the expression
of pro-fibrogenic and pro-tumorigenic connective tissue
growth factor (CTGF) in hepatocytes. These findings indicate
the existence of FGF15/19-triggered CTGF-mediated
paracrine effects on stellate cells, and an amplification
mechanism for the hepatocarcinogenic effects of FGF15/19
via the production of CTGF (Table 1; Uriarte et al.,
2015).
In contrast, FGF15/19 is significantly overexpressed in
human HCC. Serum FGF15/19 levels in patients with HCC
are significantly decreased after hepatectomy. The FGF15/19
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protein increases the proliferation and inversion capabilities of
cultured human hepatocellular carcinoma cells. These findings
indicate that FGF15/19 functions as an autocrine/paracrine factor
in human HCC (Miura et al., 2012). Epithelial-mesenchymal
transition is a key event in metastasis and plays a critical
role in the progression of HCC (van Zijl et al., 2009). The
expression of FGF15/19 is significantly elevated and negatively
associated with the expression of E-cadherin in HCC tissues
and cell lines. Ectopic FGF15/19 expression promotes epithelial-
mesenchymal transition and invasion in epithelial-like HCC
cells through the repression of E-cadherin expression, whereas
FGF15/19 knockdown enhances E-cadherin expression and,
hence, diminishes epithelial-mesenchymal transition traits in
mesenchymal-like HCC cells. However, FGF15/19 knockdown
cannot abrogate epithelial-mesenchymal transition traits in the
presence of glycogen synthase kinase 3β (GSK3β) inhibitors.
FGF15/19-induced epithelial-mesenchymal transition may be
markedly attenuated when FGFR4 is knocked out. These findings
indicate that the FGFR4/GSK3β/β-catenin axis plays a pivotal
role in FGF15/19-induced epithelial-mesenchymal transition in
HCC cells (Table 1; Zhao et al., 2015).
Genomic analyses promise to improve tumor characterization
in order to optimize personalized treatments for patients with
HCC. Exome sequencing analyses of HCC indicate that the gene
locus including FGF15/19 is amplified at advanced stages in
aggressive HCC (Table 1; Schulze et al., 2015).
CONCLUSIONS
FGFs are growth factors with diverse functions in development,
health, and disease. Among 22 FGFs, several FGFs act as
paracrine or endocrine signals in liver development, health,
and disease. FGF8 and FGF10 function as paracrine signals
in embryonic liver development. FGF7 and FGF9 also act as
paracrine signals in repair in response to liver injury. In addition,
FGF5, FGF8, FGF9, FGF17, and FGF18 play roles as paracrine
signals in the development and progression of hepatocellular
carcinoma. In contrast, FGF15/19 and FGF21 are endocrine
signals. FGF15/19, which is produced in the ileum, is involved
in bile acid metabolism and gallbladder filling in the liver.
FGF15/19 is also a postprandial, insulin-independent activator of
hepatic protein and glycogen synthesis. Furthermore, FGF15/19
is involved in liver regeneration and hepatocellular carcinoma.
FGF21 is a hepatokine produced in the liver. It regulates glucose
and lipid metabolism. Serum FGF21 levels are increased in
NAFLD. FGF21 also protects against NAFLD. These findings
provide new insights into the roles of FGFs in the liver and
potential therapeutic strategies for hepatic disorders.
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